On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the September 2025 CRG meeting. Actions in this consultation include:
- Betula verrucosa for allergic rhinitis or conjunctivitis – green (specialist initiation)
- Idebenone for visual impairment in Leber’s hereditary optic neuropathy – red
- Guselkumab for ulcerative colitis and Crohn’s disease – red
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Monday 29th September 2025. To take part, visit the consultations page.